On Wednesday, GE HealthCare GEHC reported first-quarter 2025 adjusted EPS of $1.01, which beat the consensus of 91 cents. It was up from 90 cents a year ago.The company reported sales of $4.78 billion, beating the consensus of $4.66 billion.Revenues increased 3% on reported and 4% on an organic basis year-over-year. Revenue growth was broad-based across all segments, with overall strength in the U.S.Total company book-to-bill was 1.09 times. Total company orders increased a record 10% organically year-over- ...

For the quarter ended March 2025, GE HealthCare Technologies (GEHC) reported revenue of $4.78 billion, up 2.7% over the same period last year. EPS came in at $1.01, compared to $0.90 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.66 billion, representing a surprise of +2.57%. The company delivered an EPS surprise of +10.99%, with the consensus EPS estimate being $0.91.While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.90 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.99%. A quarter ago, it was expected that this medical technology company would post earnings of $1.26 per share when it actually produced earnings of $1.45, delivering a surprise of 15.08%.Over the la ...

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $4.8 billion, with organic revenue growth of 4% and high single-digit growth in the U.S. market [10][11] - Adjusted EPS for the quarter was $1.01, reflecting a 12% year-over-year increase, while free cash flow was $98 million, down $175 million from the previous year [12][19] - The adjusted EBIT margin was 15%, up 30 basis points year-over-year, driven by volume and productivity improvements [12][13] Business Line Data and Key Metrics Changes - Imaging segment organic revenue grew 5% year-over-year, with EBIT margin up 130 basis points due to productivity and volume [14][15] - Advanced Visualization Solutions saw a 3% increase in organic revenue, with EBIT margin increasing by 10 basis points [16] - Patient Care Solutions experienced 2% organic revenue growth, but EBIT margin declined by 450 basis points due to investments and product mix [17] - Pharmaceutical Diagnostics achieved 8% organic growth with an EBIT margin above 32% [18] Market Data and Key Metrics Changes - The U.S. market showed strong demand, particularly in imaging products focused on cardiology and oncology, contributing to record double-digit orders growth [5][6] - The company noted a significant backlog of $20.6 billion, up $1.9 billion year-over-year, indicating strong market demand [11] Company Strategy and Development Direction - The company is focused on mitigating tariff impacts and optimizing its supply chain, with expectations of reduced tariff impacts in 2026 [8][9] - Continued investment in R&D is prioritized, with a commitment to innovation and product leadership, including the launch of new products like radiopharmaceuticals [12][25] - The company aims to enhance its market presence and drive growth through strategic M&A opportunities [20][88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in operational execution despite macroeconomic challenges, with an updated full-year guidance reflecting organic revenue growth of 2% to 3% [21][22] - The company anticipates a negative sales performance in China for the first half of 2025, with expectations of sequential improvement in the second half [22][40] - Management remains focused on maintaining long-term innovation investments while controlling discretionary expenses [27][81] Other Important Information - The company announced a share repurchase program authorization of $1 billion [20] - The first commercial doses of Flurcado were delivered, and the company is on track with its planned rollout [18][70] Q&A Session Summary Question: Can you elaborate on the tariff impact and mitigation efforts? - The estimated tariff impact for 2025 is $0.85 per share, with a significant portion expected in Q2, Q3, and Q4. Mitigation efforts include duty drawback and dual sourcing strategies [31][33][34] Question: What is the outlook for China and the impact of VBP? - The company expects a mid-single-digit decline in China for the first half of 2025, with no significant changes in market sentiment [39][40] Question: How are you managing R&D and operational spending amid tariff impacts? - The company is controlling spending in SG&A while protecting key investments in R&D and sales to support product launches [81][82] Question: What is the status of Flurcado and its market potential? - Flurcado is on track for a successful launch, with expected revenue of $30 million in 2025 and positive clinical feedback [70][71] Question: How do you view the potential risks from rare earth element export limitations? - The company does not foresee significant long-term issues from rare earth element limitations, as it has multiple sourcing strategies in place [108][109]

GE HealthCare Technologies (GEHC) Q1 2025 Earnings Call April 30, 2025 08:30 AM ET Company Participants Carolynne Borders - Chief Investor Relations OfficerPeter Arduini - President & CEOJames Saccaro - VP & CFOVijay Kumar - Senior Managing DirectorDavid Roman - Managing DirectorJoanne Wuensch. - Managing DirectorAnthony Petrone - Managing Director Conference Call Participants Lawrence Biegelsen - Senior Medical Device Equity Research AnalystJason Bednar - Senior Research AnalystRobert Marcus - AnalystCraig ...

1Q 2025 Earnings Presentation April 30, 2025 © 2025 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Forward-looking statements and additional information This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "estimate," "potential," "position," "forecast," "target," "guidance," "outloo ...

Financial Performance - Total revenues for the three months ended March 31, 2025, were $4,777 million, representing a 3% increase year-over-year and a 4% organic growth [164]. - Operating income increased to $629 million, up 17% from $540 million in the same period last year, with an operating margin of 13.2% [165]. - Net income attributable to GE HealthCare rose to $564 million, a 51% increase compared to $374 million in the prior year [165]. - Imaging segment revenues were $2,140 million, growing 4% year-over-year, driven by strong performance in Molecular Imaging and Computed Tomography [166]. - PDx segment revenues increased by 6% to $632 million, supported by growth in both price and volume [166]. - USCAN revenues grew by 7% to $2,237 million, with significant contributions from PDx and Imaging segments [166]. - Adjusted EBIT was $715 million, reflecting a 5% increase from the previous year, with an adjusted EBIT margin of 15.0%, up 30 basis points [185]. - Organic revenue for the three months ended March 31, 2025, was $4,842 million, a 4% increase from $4,650 million in the prior year [182]. - Adjusted net income was $464 million, a 12% increase from $413 million in the previous year [188]. - Adjusted earnings per share for Q1 2025 was $1.01, an increase of 12.2% from $0.90 in Q1 2024 [190]. Expenses and Costs - Research and development expenses were $344 million, up from $324 million in the previous year [161]. - Operating expenses increased by $21 million, primarily due to a $20 million increase in R&D investments [167]. - Cost of products sold decreased by $4 million, resulting in a 160 basis point reduction as a percentage of sales of products [167]. - Gross profit increased by $111 million, representing a 120 basis point improvement as a percentage of total revenues, primarily due to a reduction in cost of products sold [167]. Cash Flow and Debt - Free cash flow for Q1 2025 decreased by 64% to $98 million, down from $274 million in Q1 2024 [197]. - Cash generated from operating activities in Q1 2025 was $250 million, a decrease of 40.4% compared to $419 million in Q1 2024 [199]. - Total debt as of March 31, 2025, was $8,759 million, down from $8,951 million as of December 31, 2024, due to a $250 million repayment of the Term Loan Facility [212]. - The weighted average interest rate for the company's debt was 5.93% for Q1 2025 [213]. - As of March 31, 2025, the company had $2,473 million in cash, cash equivalents, and restricted cash, along with access to $3,500 million in revolving credit facilities [198]. Tax and Investments - The effective tax rate for Q1 2025 was 15.0%, a decrease from 24.2% in Q1 2024 [193]. - Cash used for investing activities in Q1 2025 was $407 million, primarily for the acquisition of the remaining 50% interest in NMP and additions to PP&E [203]. - Capital expenditures for Q1 2025 were $152 million, compared to $145 million in Q1 2024, focused on manufacturing capacity expansion and new product introductions [209]. Strategic Initiatives - The company continues to monitor the impact of tariffs imposed by the U.S. on imports from China, Mexico, and Canada, which could materially affect financial results [153]. - The 2024 stimulus program in China is expected to create long-term opportunities for the company, despite short-term revenue delays [155]. - The company authorized a share repurchase program for up to $1,000 million of common stock on April 30, 2025 [211]. Segment Performance - Imaging segment EBIT increased by $33 million to $199 million, driven by cost productivity and sales volume growth [174]. - The company generated revenues of $64 million from Russia and Ukraine for the three months ended March 31, 2025, down from $77 million in the same period last year [156].

GE HealthCare President and CEO Peter Arduini said, "First quarter results reflect strong execution as we start the year with robust revenue, orders and profit growth, which were driven by strength in the U.S. We remain focused on delivering on our precision care and growth acceleration strategies, underscored by the closing of our acquisition of Nihon Medi- Physics, which we expect will increase global access to our next-generation radiopharmaceuticals. Regarding the current global trade environment, we ar ...

GE HealthCare Technologies Inc. (GEHC) is scheduled to report first-quarter 2025 results on April 30, before market open.In the last reported quarter, the company’s adjusted earnings per share of $1.45 beat the Zacks Consensus Estimate by 15.1%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Let us look at how things have shaped up for GEHC prior to the announcement.Factors That Might Have Driven GEHC’s Q1 PerformanceGE HealthCare is poised to benefit from ongoing robust procedure v ...

According to the collective judgment of analysts, 'Revenues- Imaging' should come in at $2.03 billion. The estimate indicates a year-over-year change of -17.8%. Based on the collective assessment of analysts, 'Revenues- Ultrasound' should arrive at $1.22 billion. The estimate suggests a change of +48.5% year over year. Analysts on Wall Street project that GE HealthCare Technologies (GEHC) will announce quarterly earnings of $0.91 per share in its forthcoming report, representing an increase of 1.1% year ove ...